Craig C. Hopkinson - 18 Feb 2023 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
Issuer symbol
ALKS
Transactions as of
18 Feb 2023
Net transactions value
-$448,625
Form type
4
Filing time
22 Feb 2023, 15:56:07 UTC
Previous filing
05 Dec 2022
Next filing
24 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +8,722 +48% 26,716 18 Feb 2023 Direct F1
transaction ALKS Ordinary Shares Tax liability $74,554 -2,656 -9.9% $28.07 24,060 18 Feb 2023 Direct
transaction ALKS Ordinary Shares Options Exercise +10,095 +42% 34,155 20 Feb 2023 Direct F1
transaction ALKS Ordinary Shares Tax liability $106,105 -3,780 -11% $28.07 30,375 20 Feb 2023 Direct
transaction ALKS Ordinary Shares Award +22,195 +73% 52,570 20 Feb 2023 Direct F2
transaction ALKS Ordinary Shares Tax liability $183,185 -6,526 -12% $28.07 46,044 20 Feb 2023 Direct
transaction ALKS Ordinary Shares Options Exercise +6,875 +15% 52,919 21 Feb 2023 Direct F1
transaction ALKS Ordinary Shares Tax liability $84,782 -3,053 -5.8% $27.77 49,866 21 Feb 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Restricted Stock Unit Award Options Exercise -8,722 -25% 26,167 18 Feb 2023 Ordinary Shares 8,722 Direct F1, F3
transaction ALKS Restricted Stock Unit Award Options Exercise -10,095 -50% 10,096 20 Feb 2023 Ordinary Shares 10,095 Direct F1, F4
transaction ALKS Restricted Stock Unit Award Options Exercise -6,875 -100% 0 21 Feb 2023 Ordinary Shares 6,875 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 20, 2020 with a three-year performance period that ended on December 31, 2022 (the "2020 PRSUs"). The vesting of this portion of the 2020 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2020 PRSUs.
F3 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.
F4 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.
F5 This award is fully vested in accordance with its terms.